Patents by Inventor Gerald O'Sullivan

Gerald O'Sullivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORALLY ADMINISTERED BACTERIA AS VEHICLES FOR SYSTEMIC DELIVERY OF AGENTS
    Publication number: 20150359909
    Abstract: The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth.
    Type: Application
    Filed: July 14, 2015
    Publication date: December 17, 2015
    Inventors: Gerald O'SULLIVAN, Mark TANGNEY, Douwe VAN SINDEREN, Michelle CRONIN
  • NON-VIRAL VECTOR
    Publication number: 20150307897
    Abstract: The present invention provides a non-viral vector which comprises a sequence encoding an RNA replicase and a nuclear localisation sequence. The vector may also comprise a nucleotide sequence of interest (NOI). The vector may be used to deliver an NOI to a target cell.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 29, 2015
    Inventors: Declan Soden, Gerald O'Sullivan, Patrick Forde
  • Apparatus for use in the prophylaxis or treatment of tissue
    Patent number: 8545497
    Abstract: Apparatus (20) for carrying out a prophylactic or treatment procedure on tissue comprises a device (21) having a chamber (22) and at least one active element such as an electrode (23) within the chamber (22). The chamber (22) has an opening (26) through which tissue is drawn into the chamber (22). Means for drawing the tissue into the chamber may comprise a vacuum lumen with vacuum orifices (25) in the chamber (22). Treatment such as electroporation may be applied to tissue in the chamber (22).
    Type: Grant
    Filed: September 22, 2006
    Date of Patent: October 1, 2013
    Assignee: University College Cork—National University of Ireland, Cork
    Inventors: Anthony Morrissey, Declan Soden, Gerald O'Sullivan, Christopher Collins, Colum Dunne, John Piggott, Denton A. M Prior, Andrew Watson, Peter McGeehin
  • ORALLY ADMINISTERED BACTERIA AS VEHICLES FOR SYSTEMATIC DELIVERY OF AGENTS
    Publication number: 20120189550
    Abstract: The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth.
    Type: Application
    Filed: July 16, 2010
    Publication date: July 26, 2012
    Applicant: UNIVERSITY COLLEGE CORK-NATIONAL UNIVERSITY OF IRELAND, CORK
    Inventors: Gerald O'Sullivan, Mark Tangney, Douwe Van Sinderen, Michelle Cronin
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20080057109
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: January 29, 2007
    Publication date: March 6, 2008
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Apparatus for use in the prophylaxis or treatment of tissue
    Publication number: 20070179535
    Abstract: Apparatus (20) for carrying out a prophylactic or treatment procedure on tissue comprises a device (21) having a chamber (22) and at least one active element such as an electrode (23) within the chamber (22). The chamber (22) has an opening (26) through which tissue is drawn into the chamber (22). Means for drawing the tissue into the chamber may comprise a vacuum lumen with vacuum orifices (25) in the chamber (22). Treatment such as electroporation may be applied to tissue in the chamber (22).
    Type: Application
    Filed: September 22, 2006
    Publication date: August 2, 2007
    Inventors: Anthony Morrissey, Declan Soden, Gerald O'Sullivan, Christopher Collins, Colum Dunne, John Piggott, Denton Prior, Andrew Watson, Peter McGeehin
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20070141039
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: June 29, 2006
    Publication date: June 21, 2007
    Applicants: University College Cork - National University of Ireland, Cork
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Use of lactobacillus salivarius
    Publication number: 20060292133
    Abstract: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.
    Type: Application
    Filed: December 20, 2005
    Publication date: December 28, 2006
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Probiotic bifidobacterium strains
    Publication number: 20060121015
    Abstract: A Bifidobacterium strain, AH208, AH209, AH210, AH211, AH212 or AH214 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: June 10, 2005
    Publication date: June 8, 2006
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Formulation comprising a bacterial strain
    Publication number: 20060088514
    Abstract: An injectable formulation of a bacterial strain such as a Lactobacillus salivarius strain is useful in treating of inflammatory disorders such as colitis or arthritis.
    Type: Application
    Filed: September 29, 2005
    Publication date: April 27, 2006
    Inventors: Liam O'Mahony, Fergus Shanahan, Barry Kiely, John Collins, Gerald O'Sullivan
  • Probiotic lactobacillus salivarius strains
    Publication number: 20060078547
    Abstract: A Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants thereof are useful in the prophylaxis and/or treatment of inflammatory activity especially undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome.
    Type: Application
    Filed: April 14, 2005
    Publication date: April 13, 2006
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan, Barry Kiely
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20060002908
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: October 29, 2004
    Publication date: January 5, 2006
    Applicants: National University
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20050214272
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: October 4, 2004
    Publication date: September 29, 2005
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Use of lactobacillus salivarius
    Publication number: 20050084482
    Abstract: Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.
    Type: Application
    Filed: March 19, 2004
    Publication date: April 21, 2005
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Bifidobacterium in the treatment of inflammatory disease
    Publication number: 20050074441
    Abstract: A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.
    Type: Application
    Filed: February 23, 2004
    Publication date: April 7, 2005
    Inventors: John Collins, Gerald O'Sullivan, Liam O'Mahony, Fergus Shanahan
  • Probiatic product
    Publication number: 20020081311
    Abstract: An adherence factor comprises a cell wall associated adhesin derived from Lactobacillus or a derivative, fragment, precursor or mutant of the adhesin, the adherence factor mediating adherence to epithelial cells and modulating gene expression to improve gut barrier function and gastrointestinal tract homeostasis.
    Type: Application
    Filed: May 14, 2001
    Publication date: June 27, 2002
    Inventors: Fergus Shanahan, John Kevin Collins, Barry Kialy, Colum Dunne, Gerald O'Sullivan, Liam O'Mahony